FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304316> ?p ?o ?g. }

• W4367304316 abstract "<h3>Objective:</h3> To review the incidence of progressive multifocal leukoencephalopathy (PML) associated with monoclonal antibody (mAb) therapies, specifically anti-CD20 medications used in multiple sclerosis (MS). <h3>Background:</h3> PML is an opportunistic and fatal inflammatory disease of the central nervous system, which occurs almost exclusively in immunocompromised hosts; therefore, patients receiving mAb immunotherapy become an at-risk population. B cell-depleting mAbs targeting CD20+ cells have become widely used in MS. Although their efficacy is well-known, their associated risk of PML, especially among those without previous disease-modifying therapy (DMT) exposure, has been insufficiently studied. <h3>Design/Methods:</h3> A systematic literature review of PubMed, Google Scholar, EMBASE, and Scopus was conducted by two independent researchers from June 1, 1997, to July 10, 2022. Further data was obtained from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database and individual pharmaceutical companies (Genentech, Novartis, and TG Therapeutics). Carryover cases from prior exposure to other immunosuppressants were excluded. <h3>Results:</h3> Between 2015 and 2017, 10 cases of PML were reported in the FAERS database among 334 MS patients taking rituximab; two had previously received natalizumab, leaving eight cases in total. Rituximab-associated PML was also seen in lymphoproliferative disorders (n=52), rheumatoid arthritis (n=9), and granulomatosis with polyangiitis (n=2). Two fatal PML cases were found in MS patients taking ocrelizumab. No cases of PML were reported with ofatumumab in MS; however, 5 cases were reported in chronic lymphocytic leukemia. PML has not been observed with ublituximab, which is currently under FDA review. Among other DMTs, PML was frequently reported with natalizumab (n=884), fingolimod (n=30), dimethyl fumarate (n=12), and alemtuzumab (n=1). <h3>Conclusions:</h3> Anti-CD20 therapies are a safe class of medications with a low infectious risk for PML, especially compared to other mAbs used in MS, such as natalizumab. Nonetheless, risk stratification in susceptible individuals, as done with natalizumab, could prove beneficial with all mAb treatments. <b>Disclosure:</b> Dr. Sharma has nothing to disclose. Dr. Srivastava has nothing to disclose. Dr. JENA has nothing to disclose. Dr. Kakara has nothing to disclose. Dr. Sriwastava has nothing to disclose. Maha Daimee has nothing to disclose. Dr. Xu has nothing to disclose." @default.
• W4367304316 created "2023-04-29" @default.
• W4367304316 creator A5026702228 @default.
• W4367304316 creator A5026759644 @default.
• W4367304316 creator A5038906848 @default.
• W4367304316 creator A5053003832 @default.
• W4367304316 creator A5065518601 @default.
• W4367304316 creator A5081913408 @default.
• W4367304316 creator A5082816500 @default.
• W4367304316 date "2023-04-25" @default.
• W4367304316 modified "2023-09-27" @default.
• W4367304316 title "Progressive Multifocal Leukoencephalopathy (PML) With Anti-CD20 and Other Monoclonal Antibody (mAb) Therapies in Multiple Sclerosis (P8-3.016)" @default.
• W4367304316 doi "https://doi.org/10.1212/wnl.0000000000202034" @default.
• W4367304316 hasPublicationYear "2023" @default.
• W4367304316 type Work @default.
• W4367304316 citedByCount "0" @default.
• W4367304316 crossrefType "proceedings-article" @default.
• W4367304316 hasAuthorship W4367304316A5026702228 @default.
• W4367304316 hasAuthorship W4367304316A5026759644 @default.
• W4367304316 hasAuthorship W4367304316A5038906848 @default.
• W4367304316 hasAuthorship W4367304316A5053003832 @default.
• W4367304316 hasAuthorship W4367304316A5065518601 @default.
• W4367304316 hasAuthorship W4367304316A5081913408 @default.
• W4367304316 hasAuthorship W4367304316A5082816500 @default.
• W4367304316 hasConcept C126322002 @default.
• W4367304316 hasConcept C143998085 @default.
• W4367304316 hasConcept C18031839 @default.
• W4367304316 hasConcept C203014093 @default.
• W4367304316 hasConcept C2776995267 @default.
• W4367304316 hasConcept C2778714382 @default.
• W4367304316 hasConcept C2778843634 @default.
• W4367304316 hasConcept C2779338263 @default.
• W4367304316 hasConcept C2780640218 @default.
• W4367304316 hasConcept C2780644213 @default.
• W4367304316 hasConcept C2780653079 @default.
• W4367304316 hasConcept C2781004633 @default.
• W4367304316 hasConcept C2908647359 @default.
• W4367304316 hasConcept C71924100 @default.
• W4367304316 hasConcept C99454951 @default.
• W4367304316 hasConceptScore W4367304316C126322002 @default.
• W4367304316 hasConceptScore W4367304316C143998085 @default.
• W4367304316 hasConceptScore W4367304316C18031839 @default.
• W4367304316 hasConceptScore W4367304316C203014093 @default.
• W4367304316 hasConceptScore W4367304316C2776995267 @default.
• W4367304316 hasConceptScore W4367304316C2778714382 @default.
• W4367304316 hasConceptScore W4367304316C2778843634 @default.
• W4367304316 hasConceptScore W4367304316C2779338263 @default.
• W4367304316 hasConceptScore W4367304316C2780640218 @default.
• W4367304316 hasConceptScore W4367304316C2780644213 @default.
• W4367304316 hasConceptScore W4367304316C2780653079 @default.
• W4367304316 hasConceptScore W4367304316C2781004633 @default.
• W4367304316 hasConceptScore W4367304316C2908647359 @default.
• W4367304316 hasConceptScore W4367304316C71924100 @default.
• W4367304316 hasConceptScore W4367304316C99454951 @default.
• W4367304316 hasLocation W43673043161 @default.
• W4367304316 hasOpenAccess W4367304316 @default.
• W4367304316 hasPrimaryLocation W43673043161 @default.
• W4367304316 hasRelatedWork W2272446420 @default.
• W4367304316 hasRelatedWork W2511874056 @default.
• W4367304316 hasRelatedWork W2564051232 @default.
• W4367304316 hasRelatedWork W2886272958 @default.
• W4367304316 hasRelatedWork W2908850704 @default.
• W4367304316 hasRelatedWork W2965779047 @default.
• W4367304316 hasRelatedWork W3206160011 @default.
• W4367304316 hasRelatedWork W4285384838 @default.
• W4367304316 hasRelatedWork W4360619161 @default.
• W4367304316 hasRelatedWork W4362458038 @default.
• W4367304316 isParatext "false" @default.
• W4367304316 isRetracted "false" @default.
• W4367304316 workType "article" @default.